Insulet, Eli Lilly join for OmniPod delivery of U200 concentrated insulin
Insulet Corporation recently announced a development agreement with Eli Lilly to develop a version of the OmniPod tubeless insulin delivery system designed to delivery Lilly’s Humalog 200 units/mL insulin, according to a company press release.
The agreement will enable the companies to develop the first insulin pump specifically designed for delivery of the Humalog U200 insulin. The new system would help patients improve glycemic control without the use of multiple daily injections.
“We are thrilled to partner with Lilly to develop the first insulin pump specifically designed for Humalog U200 insulin,” Patrick Sullivan, CEO of Insulet Corporation, said in the release. “This partnership allows Insulet to deliver the advantages of our OmniPod System to individuals worldwide with higher insulin requirements so they can better control their diabetes. Using Humalog U200 in OmniPod’s tubeless design effectively doubles the number of insulin units available to users in a single pod. This will provide the freedom and ease of use of our OmniPod System to a broader range of individuals living with diabetes.”